TL;DR
This study identifies β-ecdysterone, a natural compound from "medicine and food homology" (MFH) products, as a promising therapeutic for cardiac remodeling. It achieves this by targeting the NRF2 pathway involved in oxidative stress and also influences central nervous system regulation of the heart, offering a novel approach to cardiovascular disease treatment.
What Problem Does This Paper Address?
Cardiovascular diseases remain a leading cause of death, and cardiac remodeling—the heart's maladaptive response to injury—is a key driver of heart failure. While natural products offer safer alternatives to synthetic drugs, their therapeutic potential for cardiovascular diseases is often unclear due to a lack of robust scientific evidence and systematic screening. This paper aims to bridge this gap by identifying functional MFH compounds that can combat cardiac remodeling, focusing on a comprehensive, high-throughput approach that integrates bioinformatics, computational drug design, and experimental validation.
Methods
The researchers employed a multi-pronged approach:
- Bioinformatics and Data Mining: They used databases like DisGeNet and GeneCards to identify key targets and pathways in cardiac remodeling, pinpointing oxidative stress and the NRF2 pathway.
- Computational Drug Design (CADD): They screened a database of MFH compounds (MFCD) for molecules that could competitively bind to KEAP1, thereby releasing NRF2. This involved molecular docking and ADME (Absorption, Distribution, Metabolism, Excretion) predictions.
- In Vivo and Ex Vivo Experiments: Promising compounds were tested in animal models (ISO-induced cardiac remodeling) and cell cultures (cardiomyocytes, fibroblasts) to assess their efficacy in ameliorating cardiac remodeling, oxidative stress, and inflammation.
- Transcriptomics: They analyzed gene expression in cardiac and medullary tissues to understand the molecular mechanisms and central-peripheral interactions involved.
- Neurotransmitter Metabolomics and rs-fMRI: These techniques were used to investigate the impact of the compound on the central nervous system's regulation of cardiac function.
- Weighted Correlation Network Analysis (WGCNA): This was used to identify key regulatory genes and pathways involved in the central-peripheral crosstalk.
Datasets
- Medical and Food Homology Compound Database (MFCD): This database was curated by the study, initially containing 110 known MFH natural products and expanded to include 3907 homologous components.
- Public Databases: DisGeNet, GeneCards, String, Cytoscape, UCSC, PROMO, PubMed, TCMSP, and RCSB (for protein structures).
- Animal Models: Isoproterenol (ISO)-induced cardiac remodeling in mice, as well as aortic constriction (TAC) and L-NAME-induced hypertension models for initial target validation.
Key Insights and Ideas
- NRF2 as a Central Player: The study strongly implicates NRF2 as a critical regulator of oxidative stress in cardiac remodeling, making it a prime target for therapeutic intervention.
- β-ecdysterone's Dual Action: Beyond its direct effects on cardiac cells, β-ecdysterone also influences the central nervous system's regulation of the heart, suggesting a more holistic therapeutic approach.
- Central-Peripheral Crosstalk: The research highlights the intricate interplay between the central nervous system and the heart in cardiac remodeling, a mechanism that β-ecdysterone appears to modulate.
- Novel Gene Associations: The study identifies potential roles for genes like Slc41a3 and Dhx37 in cardiac remodeling and their regulation by β-ecdysterone, opening new avenues for research.
Key Results
- β-ecdysterone Identified: Through CADD and screening, β-ecdysterone was identified as the most promising NRF2 enhancer from the MFCD library.
- Amelioration of Cardiac Remodeling: β-ecdysterone demonstrated dose-dependent efficacy in ameliorating cardiac hypertrophy and fibrosis in both in vivo and ex vivo models.
- Reduced Oxidative Stress: The compound effectively countered oxidative stress markers (MDA) and modulated antioxidant enzymes.
- Central Nervous System Modulation: rs-fMRI showed that β-ecdysterone suppressed activity in the paraventricular nucleus (PVN), a key sympathetic nerve center. Neurotransmitter analysis revealed a decrease in norepinephrine (NE) and its metabolite DHPG.
- Transcriptomic Signatures: Transcriptome analysis revealed that ISO treatment affected energy metabolism and extracellular matrix remodeling, while β-ecdysterone influenced neurotransmitter-related pathways and genes like Slc41a3 and Dhx37.
- NRF2 Mediation: Knockdown of NRF2 significantly hindered the beneficial effects of β-ecdysterone on cardiomyocytes, confirming NRF2's mediating role.
Limitations and Future Work
- Mechanism Research: The authors acknowledge that direct evidence clarifying the specific regulatory relationship of NRF2 with Slc41a3 and Dhx37 in cardiac remodeling and β-ecdysterone treatment was not fully established, emphasizing the need for further in-depth mechanistic research.
- Data Mining Focus: The study's objective was primarily data mining, meaning extensive mechanism research and verifications were not performed for all identified pathways.
- Future Directions: The study suggests future research should focus on elucidating the regulatory mechanisms of NRF2, Slc41a3, and Dhx37 in anti-oxidative stress processes and cardiac remodeling. The potential of MFH compounds for cardiovascular diseases warrants further investigation.
Summary updated